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Abstract
During maturing antibody responses the increase in affinity for target antigens is achieved by genetic diversification of
antibody genes followed by selection for improved binding. The effect this process has on the specificity of antibody for
variants of the antigen is not well-defined, despite the potential role of antibody diversification in generating enhanced
protection against pathogen escape mutants, or novel specificities after vaccination. To investigate this, a library of single
amino-acid substitution epitope variants has been screened with serum obtained at different time-points after
immunization of mice with the HIV gp41 peptide epitope ELDKWA. The serum IgG response is shown to mature and
increase affinity for ELDKWA, and the titre and affinity of IgG against most epitope variants tested increases. Furthermore
there is a bias towards high affinity serum IgG binding to variant epitopes with conservative substitutions, although
underlying this trend there is also significant binding to many epitopes with non-conservative substitutions. Thus,
maturation of the antibody response to a single epitope results in a broadening of the high-affinity response toward variant
epitopes. This implies that many pathogen epitope escape variants that could manifest as single amino-acid substitutions
would not emerge by escaping immune surveillance.
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Introduction
The relationship between serum antibody affinity and specificity
is poorly understood. It is often assumed that as antibodies
increase in affinity they also become more specific, and at a trivial
level this is likely. A single high affinity antibody might only bind
one or a few targets with strength. The serum response to T-
dependent antigens is, however, a composite of antibodies from
many clones, and it has long been known that ‘specific’ antibody
responses produce antibodies that react with a variety of unrelated
antigens [1]. As an antibody response progresses the number of V-
regions or CDR3s used against some antigens may reduce [2,3]
although against others numbers may increase [4], and therefore
while at a coarse level the repertoire may become more restricted,
somatic hypermutation in germinal centers diversifies V-genes to
such an extent that at the sequence level many cells have different
receptors [2,3,5–7]. These different antibodies would each have
slightly different antigen binding regions that may have specificity
beyond that for the immunizing epitope [8,9] and there is also
evidence that somatic mutation can change antibody specificity
altogether [10,11]. The genetic diversification caused by new V-
gene recruitment and somatic hypermutation has, therefore, the
potential to expand the number of epitopes bound by a developing
antibody response. Although generation of frank self-reactivity can
lead to rapid apoptosis in germinal centres [12–14], and so defines
an extreme limit of the diversification of specificity, the overall
scope of reactivity produced during antibody maturation is
currently little understood.
This issue is important, however, because it has a bearing on the
related subjects of how broad the antibody reactivity induced by
vaccine epitopes is, and similarly, the degree to which antibody
responses to pathogen epitopes protect against variants of the
epitope. With perfect specificity, an antibody response would not
show binding to any epitope variants; with no specificity, a
response would show binding to all possible non-self epitopes.
Determining where on this scale of specificity in vivo responses lie,
and how they change as the response progresses, is an aim of the
study reported here.
Results
To investigate how specificity changes during an antibody
response serum IgG was screened at different times after
immunisation with the HIV gp41 epitope ELDKWA [15], against
a library of ELDKWA variants. To systematically introduce
minimal changes in the epitope, and mimic how pathogen escape
variants might manifest, a peptide library was created by
synthesising all (except cysteine to avoid thiol reactions) single
amino acid substitutions of the central LDKW sequence.
ELDKWA was chosen as the antigen because it is short and so
should not contain multiple independent epitopes, it is well
characterised, derived from a real protein and the epitope is
maintained in a linear peptide [15,16]. Further, ELDKWA is a
defined high affinity antibody epitope as it is the target of human
monoclonal 2F5, which blocks HIV infection in vivo and in vitro
[17–19]. We use 2F5 as a comparison antibody in this study.
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Eight mice were immunised with 50 ug of CELDKWAS
peptide conjugated to KLH in alum, for each time-point. The
n-terminal C was added for efficient crosslinking to carrier and
also included with the c-terminal S residue, part of the native
sequence, to avoid problems with antibodies specific for just
the terminal residue (see methods). Serum was obtained 14, 38 and
83 days after CELDKWAS immunisation. These time-points
were chosen to cover the period from the peak of the primary
response to the time by which affinity maturation has occurred;
for example see reference 21. Figure 1A shows the anti-peptide
serum IgG titres for these time points. Titres rise from day
14 to day 38, and at day 83 show similar levels to day 38. To
measure affinity maturation, sera were screened against a
peptide/carrier titration, which discriminates for high affinity
IgG binding [20,21]. Figure 1B shows that the relative affinity
of serum IgG for ELDKWA continues to rise over the time course
of the experiment, consistent with previous observations that
affinity maturation can continue for over 100 days after
immunisation [21].
Serum binding to ELDKWA variants
All serum samples, from each time point after immunisation,
were then used individually to screen the ELDKWA variants
library containing the 72 possible (except cysteine) single amino-
acid substitutions of LDKW. Serum from each individual mouse
was used at the dilution that gave an IgG absorbance reading of 1
against the native peptide. This allows a comparison of the relative
effects of substitutions on the binding of antibody from each time-
point. The results are shown in Figure 2A. For the purpose of
clarity the data for the substitutions at each particular position are
shown separately. The data in each panel have been ranked
according to the absorbance reading for each variant from day 14
serum. Readings for the native peptide and a CLAKDWE
randomised control peptide are also included in each panel.
After 14 days serum IgG binding was heavily dependent on the
K and W residues, as all substitutions in these positions severely
diminished binding. Most D position substitutions also had a large
effect on IgG binding whereas alterations at the L position had a
lesser effect but, as for the D position, this depended on the
particular substitution. After 38 days most D and all K and W
substitutions were better tolerated; serum showed higher levels of
binding to these variants than at day 14. Day 38 serum binding
became more dependent on the L residue, however, as
substitutions here reduced binding more than at day 14. Overall
the binding of day 38 serum IgG to variants increased and became
less dependent on any particular residue. This trend continued to
day 83 when levels of IgG binding to all variants was greater than
at day 38. The binding of total serum IgG to most single
substitution variants of the epitope, therefore, increased markedly
over time. The exception was for substitution at the L residue
where the binding pattern was more complex. Binding of day 83
serum to about half the variants at this position recovered after the
drop at day 38 to the levels seen at day 14.
Figure 2A also shows the binding of the anti-ELDKWA human
monoclonal 2F5. 2F5 is known to have a core recognition
sequence of D(K/R)W [16] and these data confirm this. This
figure shows how intolerant the monoclonal antibody is of epitope
variation, with only 3/54 DKW substitutions showing any
binding; demonstrating a difference in binding between single
antibodies and polyclonal sera. Figure 2B shows all the data points
from Figure 2A ranked in value for each timepoint to show the
overall trend of increasing binding to epitope variants.
High affinity binding to epitope variants
It is possible that the increased binding to epitope variants is
simply because antibody affinity for the native epitope has
increased so much that single substitutions in it do not cause a
loss of binding that can be detected here. With the high peptide to
carrier coupling ratio used (10:1) low as well as high affinity IgG
would be detected. An epitope variation that reduced antibody-
binding affinity by one or two logs from an initially high affinity
may, therefore, still bind. To further investigate this issue and to
test for high affinity binding to the variant sequences, the assay was
repeated with peptide variants that have been coupled to carrier at
low density, 1:1 peptide: ovalbumin, chosen from the results in
Figure 1B. At this coupling ratio only higher affinity IgG binding
to peptide will be detected. Any binding to epitope variants will
indicate a spreading of IgG specificity to these variants.
For brevity, as affinity maturation is continuing until day 83
(Figure 1b) we have omitted data from the day38 time-point, to
just show the total effect between the first and last time-points.
Serum from day 14 and day 83 was screened against the variant
peptide library, coupled at low density to ovalbumin, using the
same dilutions as in Figure 2. These dilutions were used, because
they were used in the peptide/carrier ratio titration, shown in
Figure 1b, and give a good discrimination of high affinity binding
when the peptide/carrier ratio is 1. The results are shown in
Figure 3A. This figure shows that at day 83 serum IgG showed a
significant level of higher affinity binding with most D, K, or W
and some L substitutions. Day 14 sera showed little high affinity
binding to any epitope variants, which is expected, as reactivity of
serum with the native peptide at this coupling ratio is low
(Figure 1B). Maturation of the response against ELDKWA is
associated, therefore, with an increase in high affinity IgG binding
to most epitope variants tested. Figure 3B shows all the data points
ranked for each timepoint, and shows that there were greater
levels of high affinity IgG binding to most variants at day 83 than
there was binding to ELDKWA at day 14. Specificity, as defined
by high affinity binding to variant sequences, has broadened after
maturation of this immune response.
Figure 3B also shows the ranked values for high affinity binding
of the monoclonal 2F5 to the epitope variants. The monoclonal
showed high affinity binding at high levels to 6/72 variants with
most of the rest showing no binding at all; this picture contrasts
with the moderate levels of high affinity binding to most variants
shown by the day 83 serum.
High affinity binding related to the type of substitution
in epitope variants
To further investigate the change in specificity of the maturing
antibody response to ELDKWA, correlation between the level of
high affinity binding to particular variants with the type of
substitution in the variant was investigated. Some substitutions will
have a greater effect on the epitope shape than others, and it
would be informative to compare the degree of change in the
epitope with the level of IgG binding. The most appropriate
measure of the change induced by single amino-acid substitutions
in protein sequences is the PAM250 score [22]. The PAM-250
matrix, which provides scores for every possible single amino-acid
substitution, has been derived by comparing the amino acid
sequences of a large set of closely related proteins to determine the
frequencies of each particular amino-acid substitution between
them. On the basis that substitutions have been evolutionarily
selected, the frequency of a particular substitution reflects how
functionally similar it is to the original amino-acid. Using the
PAM-250 matrix to score differences in epitope sequences,
therefore, provides a useful measure of the likelihood that change
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much the substitution changes the structure/function of the
epitope. Comparing these scores with the affinity of the antiserum
against the substituted peptide will provide information on how
affinity maturation changes the tolerance of antiserum binding to
pathogen epitope changes that vary from small more likely
changes to larger less likely ones.
The PAM-250 score for a substitution is usually presented as the
log of the frequency that a particular change is found after 250
evolutionary steps. Positive scores are substitutions found more
often than would be found randomly, and represent conservative
changes that alter function less. Negative scores represent
substitutions occurring less often than random and equate to
non-conservative changes [28].
The IgG binding values from Figure 3A were plotted against the
PAM250 score for each particular substitution (Figure 4). This
figure shows a positive correlation overall between IgG binding
and PAM250 score, in particular for substitutions at L, D and K,
implying that serum IgG reactivity has a bias towards conservative
changes in epitope. This bias, the slope of the trend-line; and also
whether the trend line intercepts the baseline reading of 0.13
(binding of day 83 serum to the LAKDWE control peptide) defines
the specificity of the serum, by showing the degree of change that
can be tolerated at any particular residue in the epitope.
Figure 1. Anti-ELDKWA serum IgG titre and relative affinity. A, serum IgG titre 14 (blue), 38 (green), and 83 (brown) days after immunization.
B, relative affinity of serum IgG with decreasing peptide/carrier conjugation ratio, after 14 (blue), 38 (green) and 83 (brown) days. Error bars: standard
error of the mean, from 7 (day 14) or 8 (day 38, 83) total samples from two separate immunizations.
doi:10.1371/journal.pone.0031555.g001
Diversification of Antibody Specificity
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31555The most non-conservative substitutions in the L and D residues
show baseline absorbance readings in Figure 4, and so loss of high
affinity IgG binding. This observation, combined with the positive
correlation of absorbance and PAM250 score, indicate that anti-
ELDKWA serum was more sensitive to the type of substitution at
these residues than at K and W. Conversely, at the K and W
residues, despite the overall trend toward higher binding to
epitopes with conservative changes, there was significant high
affinity IgG binding to variants with highly non-conservative
substitutions. In effect, the serum would tolerate more than a
Figure 2. Reaction of anti-ELDKWA serum IgG with epitope variants. A, mean values of reactivity with epitope variants (coupling ratio 10:1
ovalbumin), at a serum dilution that gives an absorbance of 1 against ELDKWA, after 14 (blue), 38 (green) and 83 (brown) days. Open brown triangles,
2F5 monoclonal. L, D, K, W denote the original amino-acid, small letters on x-axis denote the substitution in the variant. For clarity, values have been
ranked according to the day 14 (blue) reading. First data point in each panel is the value for ELDKWA; last data point is for the randomized epitope
sequence LAKDWE. Error bars: standard error of the mean, from 7 (day 14) or 8 (day 38, 83) total samples from two separate immunizations. B, ranked
(separately for each time point) mean reactivity of anti-ELDKWA serum IgG against all 72 epitope variants and control after 14 (blue), 38 (green) and
83 (brown) days. Open brown triangles, 2F5 monoclonal.
doi:10.1371/journal.pone.0031555.g002
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affinity IgG binding.
High affinity IgG binding did not show much bias for particular
substitutions at the W residue as the absorbance/PAM250
correlation trend-line is almost flat. Most substitutions of
tryptophan have negative PAM250 scores; with the exception of
W to R it cannot be conservatively substituted. This could explain
why substitutions of this residue showed very little correlation of
binding with the PAM250 score. As almost all substitutions at this
residue result in a gross change, serum IgG may not discriminate
between particular substitutions even though they contain different
residues.
Figure 3. Higher affinity reaction of anti-ELDKWA serum IgG with epitope variants. A, mean values of reactivity with epitope variants
(coupling ratio 1:1 ovalbumin), at the serum dilution that gives an absorbance of 1 against ELDKWA coupled 10:1 with ovalbumin, after 14 (blue) and
83 (brown) days. L, D, K, W denote the original amino-acid, small letters on x-axis denote the substitution in the variant. For clarity, values have been
ranked according to the day 14 (blue) reading. First data point in each panel is value for ELDKWA; last data point is for the randomized epitope
sequence LAKDWE. Error bars as for Figure 2A. B, ranked (separately for each time point) mean high affinity reactivity of anti-ELDKWA serum IgG
against epitope variants (coupling ratio 1:1 ovalbumin) after 14 (blue) and 83 (brown) days. Open brown triangles, 2F5 monoclonal.
doi:10.1371/journal.pone.0031555.g003
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By screening serum from a maturing antibody response against
a library of peptides we have shown that an increase in titre and
affinity of IgG is accompanied by an increase in high affinity
binding to epitope variants; that at the scale of single amino acid
differences, antibody maturation causes a broadening of antiserum
specificity, to include non-conservatively substituted epitope
variants. There were greater levels of high affinity IgG binding
to 48 of 72 variants at day 83 than there were to the native epitope
at day 14. This spread of specificity is in marked contrast to that
seen for a monoclonal antibody.
By correlating antibody binding with the degree of change
(PAM250 score) in the epitope, and considering the intersection of
the trend-line in Figure 4 with baseline readings, we can define the
specificity of the antiserum. After maturation of the response
against ELDKWA, high affinity serum specificity has spread to
certain substitutions in the L and D residue, but beyond single
substitutions in the K and W residues, as any changes here do not
completely abolish antibody binding and so additional changes
may be tolerated.
Single substitutions do not tend to cause the catastrophic loss of
antiserum binding as they mostly do with the monoclonal
antibody, but rather, a graduated reduction inpart dependant on
the degree of similarity of the substitution to the native residue.
This, as discussed below, is likely to be an effect of the
polyclonality of the antiserum, and if this provides enhanced
protection against variant pathogens it is a good reason why
humoral responses do not rapidly become monoclonal.
Although we have only analysed single substitutions in a short
epitope – and this therefore defines the scale within which we
observe a spread of specificity – the level of higher affinity binding
observed against non-conservative substitutions is still surprising.
Although the changes described here might be described as
diversification of ‘fine specificity’ [4] this cannot be simply
assumed. Changes that affect only fine specificity would not alter
the binding of an antibody to any other epitope in the set of all
possible epitopes, and this is difficult to determine. Given that
antibody maturation can involve recruitment of new VDJ
combinations as well as somatic mutation, it is conceivable that
an ongoing antibody response could introduce entirely new
binding specificities.
The observation that low affinity clones can initiate germinal
centres [23] and then undergo somatic mutation regardless of their
initial affinity [24] suggests that clones with many different V-
genes participate in the early primary response. After this point,
the selective forces acting on clones that mutate their antibody
genes are the need to continue binding antigen [25] and the
deletion of self-reactive clones [12–14]. The pressure to continue
binding antigen, at increasing affinity, might place tight constraints
on the permissible variability in the antigen-binding region, but
these constraints will vary depending on the V-gene used and
epitope type and they are currently unknown. Within these
constraints, antigen-binding regions would be free to evolve and
experience neither positive nor negative selective pressure on
mutations at residues not crucially involved in binding. This
process would cause a diversification of specificity related to the
number of genetically distinct clones. The data presented here are
Figure 4. Correlation of serum IgG binding with PAM250 value of L, D, K and W substitutions. Mean values of high affinity serum IgG
reactivity with epitope variants (from Figure 3A) plotted against the PAM250 value of the substitution in each variant. L, D, K and W refer to the
particular epitope residue substituted.
doi:10.1371/journal.pone.0031555.g004
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substitutions in epitopes, a broadening of specificity evolves during
antibody maturation. The contrast between antiserum and
monoclonal binding profiles support the notion that this effect is
caused by increasing clonality rather than increasing affinity.
Further, the notion that increased binding to epitope variants is
caused simply by an increase in affinity is inconsistent with the
data, as less IgG bound to variants substituted at the L residue at
days 38 and 83 than at day 14, even though the IgG affinity for
ELDKWA had increased at these time points.
The results presented here are consistent with the postulate that
antiserum maturation generates new specificities that can bind
pathogen escape variants. Many potential pathogen epitope
variants will manifest as single amino-acid substitutions, and we
suggest that many of these are likely to be covered by the maturing
antiserum so would never become established. One might expect
there to be a strong evolutionary pressure on antibody
diversification in the primary response to allow cover for pathogen
escape variants as well as increasing the affinity of antibodies
against the priming epitope, although the possible selective forces
driving this process are not understood. There is also the further
risk of generating self-reactivity and this makes this area complex
and difficult to study in vivo. It is particularly interesting, therefore,
that a recent study has reported that some memory clones
stimulated by infection with West Nile Virus in mice, have a
higher affinity for variants of the epitope present on the
immunising virus [29]. As it is known that high affinity clones
arise earlier in primary responses than germinal centres regress
[30], this observation supports the idea that ongoing somatic
mutation aids in the diversification of antibody specificity to allow
variant epitope binding in the manner reported here.
Methods
Ethics Statement
All experimental procedures were approved by the U.K. Home
Office under license 70/05954 and had UCL ethics committee
approval, Ref: 0897 and were performed in the Institute of Child
Health licensed animal facility.
Antigen and Immunization
CELDKWAS peptide was obtained from Sigma-Aldrich, U.K.
and coupled at saturation to maleimide activated KLH (Pierce/
Thermo Scientific, U.K.) according to manufacturers instructions.
Female, 8 week-old BALB/c mice (Harlan, U.K.) were immunized
intra-peritoneally with 50 ug alum precipitated antigen. Serum
was collected 14, 38 and 83 days after immunization. Mice were
immunized in groups of four for each time point, twice.
Peptide Library
The peptide array consisting of the 72 possible (excepting C)
single amino-acid substitution variants of the central LDKW
sequence of CELDKWA was obtained from Mimotopes, U.K.
and also included the native sequence and the randomized control
sequence CLAKDWE.
The c-terminal S residue was deliberately included in the
immunizing antigen and omitted in the screening peptides because
sera against short peptides can contain antibodies against just the
terminal residue [26]; these would mask the effects of LDKW
sequence variation on antibody binding in this assay. Each peptide
was coupled at saturation to maleimide-activated ovalbumin
(Pierce/Thermo Scientific, U.K.) according to manufacturers
instructions and purified by dialysis.
Peptide/Carrier Ratio
To alter the peptide/carrier ratio from 10 moles peptide per
mole of ovalbumin when coupled at saturating peptide concen-
tration, CELDKWA type peptides were diluted the appropriate
molar amount with the HIV TAT peptide
GGGGYGRKKRRQRRRGC and then coupled at saturating
peptide concentration. The same batch of maleimide-activated
ovalbumin was used in all experiments involving lowered peptide/
carrier ratios.
ELISA
All ELISAs were performed according ref. 27, using alkaline
phosphatase conjugates of anti-mouse or anti-human IgG (Sigma-
Aldrich, U.K.) with pNPP substrate (Sigma-Aldrich, U.K.). Wells
were coated overnight at room temperature with 2 ug ml21
peptide/ovalbumin conjugates, incubated for 4 hours at room
temperature with serum dilutions, 2 hours with alkaline phospha-
tase conjugates and 1 hour with pNPP substrate. All plates for a
particular screening series (10:1 coupling ratio or 1:1 coupling
ratio) were made at the same time and stored according to
ref. [27].
Acknowledgments
Thanks to Andy Yates, Michael Neuberger and Lindsey Goff for discussion
and advice, Lindsey Ashton for technical advice and H. Katinger for
donation of monoclonal antibody 2F5 to NIBSC.
Author Contributions
Conceived and designed the experiments: HNW. Performed the
experiments: HNW QHM. Analyzed the data: HNW QHM. Wrote the
paper: HNW.
References
1. Sperling R, Francus T, Siskind GW (1983) Degeneracy of Antibody Specificity.
J Immunol 131: 882–885.
2. Kuppers R, Zhao M, Hansmann ML, Rajewsky K (1993) Tracing B cell
development in human germinal centres by molecular analysis of single cells
picked from histological sections. EMBO J 12: 4955–4967.
3. Jacob J, Przylepa J, Miller C, Kelsoe G (1993) In situ studies of the primary
immune response to (4-hydroxy-3-nitrophenyl)acetyl. III. The kinetics of V region
mutation and selection in germinal center B cells. J Exp Med 178: 1293–1307.
4. Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, et al. (1996) The role of
somatic mutation in the generation of the protective humoral immunse response
against vesicular stomatitis virus. Immunity 5: 639–652.
5. Jacob J, Kelsoe G, Rajewsky K, Weiss U (1991) Intraclonal generation of
antibody mutants in germinal centres. Nature 354: 389–393.
6. Berek C, Berger A, Apel M (1991) Maturation of the immune response in
germinal centers. Cell 67: 1121–1129.
7. Weiss U, Zoebelein R, Rajewsky K (1991) Accumulation of somatic mutants in
the B cell compartment after primary immunization with a T cell-dependent
antigen. Eur J Immunol 22: 511–517.
8. Schildbach JF, Panka DJ, Parks DR, Jager GC, Novotny J, et al. (1991) Altered
hapten recognition by two anti-digoxin hybridoma variants due to variable
region point mutations. J Biol Chem 266: 4640–4647.
9. Fish S, Fleming M, Sharon J, Manser T (1991) Different epitope structures select
distinct mutant forms of an antibody variable region for expression during the
immune response. J Exp Med 173: 665–672.
10. Rudikoff S, Giusti AM, Cook WD, Scharff MD (1982) Single amino acid
substitution altering antigen-binding specificity. Proc Nat Acad Sci 79:
1979–1983.
11. Diamond B, Scharff MD (1984) Somatic mutation of the T15 heavy chain gives
rise to an antibody with autoantibody specificity. Proc Nat Acad Sci 81:
5841–5844.
12. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, et al. (1995) CD95
(Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+
T cells. Nature 376: 181–184.
13. Pulendran B, Kannourakis G, Nouri S, Smith KG, Nossal GJ (1995) Soluble
antigen can cause enhanced apoptosis of germinal-centre B cells. Nature 375:
331–334.
Diversification of Antibody Specificity
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e3155514. Han SH, Zheng B, Porto JD, Kelsoe GJ (1995) In situ studies of the primary
immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent,
antigen-driven B cell apoptosis in germinal centers as a mechanism for
maintaining self-tolerance. J Exp Med 182: 1635–1644.
15. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved
neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol
67: 6642–6647.
16. Tian Y, Ramesh CV, Ma X, Naqvi S, Patel T, et al. (2002) Structure-affinity
relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing
monoclonal antibody 2F5: effects of side-chain and backbone modifications and
conformational constraints. J Peptide Res 59: 264–276.
17. Conley AJ, Kessler JA, Boots LJ, Tung JS, Arnold BA, et al. (1994)
Neutralization of divergent human immunodeficiency virus type 1 variants
and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal
antibody. Proc Natl Acad Sci 91: 3348–3352.
18. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, et al. (1994) Cross-
neutralizing activity against divergent human immunodeficiency virus type 1
isolates induced by the gp41 sequence ELDKWAS. J Virol 68: 4031–4034.
19. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999)
Protection of Macaques against pathogenic simian/human immunodeficiency
virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:
4009–4018.
20. Herzenberg LA, Black SJ, Tokuhisa T, Herzenberg LA (1980) Memory B cells
at successive stages of differentiation. Affinity maturation and the role of IgD
receptors. J Exp Med 151: 1071–1087.
21. Takahashi Y, Dutta PR, Cerasoli DM, Kelsoe G (1998) In situ studies of the
primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity
maturation develops in two stages of clonal selection. J Exp Med 187: 885–895.
22. Pearson WA (1990) Methods in Enzymology, Doolittle R, ed. Academic Press,
San Diego 183: 63–98.
23. Dal Porto JM, Haberman AM, Kelsoe G, Shlomchik MJ (2002) Very low affinity
B cells form germinal centers, become memory B cells, and participate in
secondary immune responses when higher affinity competition is reduced. J Exp
Med 195: 1215–21.
24. Yang Shih T-A, Meffre E, Roederer M, Nussenzweig MC (2002) Role of BCR
affinity in T cell-dependent antibody responses in vivo. Nature Immunol 3:
570–575.
25. MacLennan ICM (1994) Germinal Centres. A Rev Immunol 12: 117–139.
26. Palfreyman JW, Aitcheson TC, Taylor PJ (1984) Guidelines for the production
of polypeptide specific antisera using small synthetic oligopeptides as
immunogens. Immunol Meth 75: 383–393.
27. Hornbeck P (1991) Current Protocols in Immunology, chapter 2, eds.
Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. John
Wiley and Sons Inc.
28. Dayhoff MO, Schwarz RM, Orcutt BC (1978) A model of evolutionary change
in proteins, in: An Atlas of Protein Sequence and Structure, National Biomedical
Research Foundation. pp 345–352.
29. Purtha WE, Tedder TF, Johnson S, Bhattacharyal D, Diamond MS (2011)
Memory B cells, but not long-lived plasma cells, possess antigen specificities for
viral escape mutants. J Exp Med 208: 2599–2606.
30. Smith KG, Light A, Nossal GJ, Tarlinton DM (1997) The extent of affinity
maturation differs between the memory and antibody-forming cell compart-
ments in the primary immune response. EMBO J 16: 2996–3006.
Diversification of Antibody Specificity
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31555